studies

breast cancer (BC), bevacizumab plus trastuzumab plus docetaxel vs. HER inhibitor, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsAVEREL, 2013 0.94 [0.68; 1.30] 0.94[0.68; 1.30]AVEREL, 201310%424NAnot evaluable progression or deaths (PFS)detailed resultsAVEREL, 2013 0.82 [0.65; 1.03] 0.82[0.65; 1.03]AVEREL, 201310%424NAnot evaluable objective responses (ORR)detailed resultsAVEREL, 2013 1.24 [0.81; 1.90] 1.24[0.81; 1.90]AVEREL, 201310%424NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-10 19:10 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 1323